We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Pethema Multiple Myeloma 2000

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: November 19, 2007
Last Update Posted: November 27, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
PETHEMA Foundation
The study objectives are to investigate the toxicity and the BUMEL response rate; in patients who reach the CR after autotransplantation, investigate if negativization of IF, influences in disease evolution; in patients in PR after autotransplantation, analyze if the second intensive procedure is capable of increasing the response rate and increasing the survival so that patients who reached the CR with the first transplantation; Patients with MM primarily resistant to the chemotherapy, investigate the efficacy of a double transplantation; patients submitted to double transplantation, control the efficacy of the second transplantation in front of allogenic transplantation.

Condition Intervention Phase
Multiple Myeloma Drug: Alternating chemotherapy Procedure: Autologous Transplantation Drug: Maintenance Procedure: Second transplantation Procedure: ALOGENIC MINI TRASPLANTATION Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multiple Myeloma 2000. Multicentric Evaluation of a Therapeutic Strategy Optimized in Multiple Myeloma. Analysis of Efficiency and Possible Pronostic Impact of Minimal Residual Disease (Measured By PCR And Citometry of Flow) in Patients With Complete Response

Resource links provided by NLM:

Further study details as provided by PETHEMA Foundation:

Enrollment: 500
Study Start Date: January 2000
Study Completion Date: February 2005
Intervention Details:
    Drug: Alternating chemotherapy

    4 cycles of alternating chemotherapy VBMCP/VBAD (every 5 weeks). VBMCP: Vcr 2 mg ev day 1, BCNU 0.5 mg/kg ev day 1, Cyclophosphamide 10 mg/kg day 1, Melphalan 0.25 mg/kg v.o. days 1-4, Prednisone 1 mg/kg v.o. days 1-4, 0.5 mg/kg days 5-8 and 0.25 mg/kg days 9-12.

    VBAD: Vcr 1 mg e.v. day 1, BCNU 30 mg/m 2 e.v. day 1, Adriamycine 40 mg/m 2 day 1, Dexamethasone 40 mg/m 2 days 1-4, 9-12 and 17-20.

    Procedure: Autologous Transplantation

    Autologous Transplantation :

    BUMEL:Busulfan, total dose 12 mg/kg (days -6 a -3; prophylaxis with difenilhidantoine) Melphalan 140 mg/m 2 , ev day -2 TASPE: To investigator criteria

    Drug: Maintenance

    At 3 months of transplantation or with >1.500 neutrophiles/ > 75.000 platelets mm 3 .

    Prednisone: 50 mg alternating days during 2 years Interferon alfa 2-b: 3 M UI s.c. Three times a week until relapse.

    Procedure: Second transplantation
    In cases that no reach CR with BUMEL is programmed second transplantation, after 4-8 months .
    ALOGENIC MINI TRASPLANTATION Fludarabine 30 mg / m 2 / day, days -7, -6, -5, -4, -3 Melphalan 70 mg / m 2 / day, day -2 Prophylaxis EICH: CsA + MTX or CsA + MOFETIL

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 69 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Less 70 years
  • ECOG 0-2
  • Symptomatic MM (pain, anemia, infection, haemorrhage, loss of weight, hypercalcemia, extramedulary plasmocytoma, creatinine >2 mg/dl).
  • No previous chemotherapy

Exclusion Criteria:

  • >70 years
  • ECOG 3-4
  • myeloma quiescent
  • cardiopathy
  • liver disfunction
  • HIV+
  • Hepatitis B-C +
  • Previous chemotherapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00560053

Sponsors and Collaborators
PETHEMA Foundation
Study Chair: Joan Bladé, Dr Hospital Clinic of Barcelona
Study Chair: Juan Jose Lahuerta, Dr Hospital Doce de Octubre Madrid
Study Chair: Adrián Alegre, Dr Hospital La Princesa Madrid
Study Chair: Anna Sureda, Dr Hospital Sant Pau Barcelona
Study Chair: Joaquín Díaz Mediavilla, Dr Hospital Clinico Madrid
Study Chair: Javier De la Rubia, Dr Hospital La Fe de Valencia
Study Chair: Joan Bargay, Dr Hospital Son Dureta Palma de Mallorca
Study Chair: Jose García-Laraña, Dr Hospital Universitario Ramon y Cajal
Study Chair: Eulogio Conde, Dr Hospital Valdecilla Santander
Study Chair: Felipe Prosper, Dr Hospital Clinico Valencia
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00560053     History of Changes
Other Study ID Numbers: PETHEMA MM-2000
First Submitted: November 15, 2007
First Posted: November 19, 2007
Last Update Posted: November 27, 2008
Last Verified: November 2008

Keywords provided by PETHEMA Foundation:
Multiple Myeloma
Alternating chemotherapy

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases